



Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species

Jung-Hyun Byun, M.D.¹, Myungsook Kim, Ph.D.¹, Yangsoon Lee , M.D.², Kyungwon Lee, M.D.¹, and Yunsop Chong, Ph.D.¹

¹Department of Laboratory Medicine, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea; ²Department of Laboratory Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Korea

Background: Anaerobic bacterial resistance trends may vary across regions or institutions. Regional susceptibility patterns are pivotal in the empirical treatment of anaerobic infections. We determined the antimicrobial resistance patterns of clinically important anaerobic bacteria, including recently named or renamed anaerobes.

Methods: A total of 521 non-duplicated clinical isolates of anaerobic bacteria were collected from a tertiary-care hospital in Korea between 2014 and 2016. Anaerobes were isolated from blood, body fluids, and abscess specimens. Each isolate was identified by conventional methods and by Bruker biotyper mass spectrometry (Bruker Daltonics, Leipzig, Germany) or VITEK matrix-assisted laser desorption ionization time-of-flight mass spectrometry (bioMérieux, Marcy-l'Étoile, France). Antimicrobial susceptibility was tested using the agar dilution method according to the CLSI guidelines. The following antimicrobials were tested: piperacillin-tazobactam, ceftiofuran, cefotetan, imipenem, meropenem, clindamycin, moxifloxacin, chloramphenicol, tetracycline, and metronidazole.

Results: Most *Bacteroides fragilis* isolates were susceptible to piperacillin-tazobactam, imipenem, and meropenem. The non-*fragilis* *Bacteroides* group (including *B. intestinalis*, *B. nordii*, *B. pyogenes*, *B. stercoris*, *B. salyersiae*, and *B. cellulosilyticus*) was resistant to meropenem (14%) and cefotetan (71%), and *Parabacteroides distasonis* was resistant to imipenem (11%) and cefotetan (95%). Overall, the *Prevotella* and *Fusobacterium* isolates were more susceptible to antimicrobial agents than the *B. fragilis* group isolates. Anaerobic gram-positive cocci exhibited various resistance rates to tetracycline (6–86%). *Clostridioides difficile* was highly resistant to penicillin, ceftiofuran, imipenem, clindamycin, and moxifloxacin.

Conclusions: Piperacillin-tazobactam, ceftiofuran, and carbapenems are highly active β -lactam agents against most anaerobes, including recently named or renamed species.

Key Words: Antimicrobial resistance pattern, Anaerobes, *Bacteroides*, Korea

Received: May 15, 2018

Revision received: July 17, 2018

Accepted: October 25, 2018

Corresponding author: Yangsoon Lee, M.D.

 <https://orcid.org/0000-0003-3821-3741>

Department of Laboratory Medicine,
Hanyang University Seoul Hospital,
Hanyang University College of Medicine,
222-1 Wangsimni-ro, Seongdong-gu,
Seoul 04763, Korea

Tel: +82-2-2290-9655

Fax: +82-2-2290-9193

E-mail: yangsoon@hanyang.ac.kr

© Korean Society for Laboratory Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

The prevalence of antibiotic resistance in anaerobes is increasing, which impacts both antibiotic treatment and patient mortality [1]. Regional susceptibility patterns are pivotal in the empiri-

cal treatment of anaerobic infections. As the resistance trends of anaerobic bacteria may vary greatly, across regions or institutions [2-4], antimicrobial susceptibility tests (ASTs) should be performed to assist with empirical antimicrobial treatment of anaerobic infections.

The CLSI has stated that routine ASTs for anaerobes are not necessary, because antibiotic resistance is often predictable [5]. Therefore, we do not always perform ASTs; however, since 1989, we have been performing periodic ASTs to investigate resistance trends among clinical bacterial isolates [6-9].

Anaerobic gram-negative bacilli (GNB) are clinically important because they have high resistance rates relative to other anaerobic bacteria [10]. Recently, a related cluster of multidrug-resistant *Bacteroides fragilis* isolates were recovered from several patients, which resulted in treatment failure in some cases [11, 12]. Furthermore, a number of anaerobic species have recently been named or renamed. *Parabacteroides distasonis* and *P. goldsteinii* were reclassified from the genus *Bacteroides*; *Alloscardovia omnicoles*, *Bulleidia extracta*, *Leptotrichia trevisanii*, *Alistipes finegoldii*, and *Alistipes onderdonkii* were named in the 2000s [13-18]. Moreover, AST data for infrequently isolated species are quite limited. Therefore, we collected rarely isolated anaerobic bacteria from clinical specimens and evaluated them using ASTs. In addition, we determined the antimicrobial resistance patterns of clinically important anaerobic bacteria, including recently named or renamed anaerobes.

METHODS

Bacterial isolates

A total of 521 non-duplicated clinical anaerobic bacteria isolates were collected from a tertiary-care hospital (Severance Hospital, Seoul, Korea) between 2014 and 2016. Anaerobes were isolated from blood, body fluids, and abscess specimens. Each isolate was identified by conventional methods, Bruker biotyper mass spectrometry (Bruker Daltonics, Leipzig, Germany), or VITEK matrix-assisted laser desorption ionization time-of-flight mass spectrometry (bioMérieux, Marcy-l'Étoile, France).

We tested a total of 230 gram-negative isolates, including 60 *Bacteroides fragilis*, 68 non-*fragilis* *Bacteroides* spp., 29 *Parabacteroides* spp., 33 *Prevotella* spp., 19 *Fusobacterium* spp., 10 other anaerobic GNB, and 11 *Veillonella* spp. Non-*fragilis* *Bacteroides* isolates were divided into two groups as follows: Group I included *B. thetaiotaomicron*, *B. caccae*, *B. uniformis*, *B. vulgatus*, and *B. ovatus*; Group II were recently classified, renamed, or infrequently isolated including *B. intestinalis*, *B. nordii*, *B. pyogenes*, *B. stercoris*, *B. salyersiae*, and *B. cellulosilyticus*. A total of 291 gram-positive isolates were tested, including 31 *Finegoldia magna*, 29 *Parvimonas micra*, 14 other gram-positive cocci (GPC), 15 *Clostridioides difficile*, 27 *Clostridium* spp., 34 *Actinomyces odontolyticus*, 23 *Actinomyces* spp., 18

Bifidobacterium spp., 38 *Eggerthella lenta*, 36 *Lactobacillus* spp., and 26 other gram-positive bacilli.

ASTs

ASTs were conducted using the agar dilution method, and minimum inhibitory concentrations (MICs) were interpreted according to the CLSI guidelines [5, 19]. The medium used was Brucella agar (Becton Dickinson, Cockeysville, MD, USA) supplemented with 5 µg/mL hemin, 1 µg/mL vitamin K₁, and 5% laked sheep blood. The following antimicrobials were tested: penicillin (Sigma Aldrich, Yongin, Korea), piperacillin-tazobactam (Yuhan, Seoul, Korea), cefoxitin (Merck Sharp & Dohme, West Point, PA, USA), cefotetan (Daiichi Pharmaceutical, Tokyo, Japan), imipenem and meropenem (Choongwae, Seoul, Korea), clindamycin (Korea Upjohn, Seoul, Korea), meropenem (Sumitomo, Tokyo, Japan), moxifloxacin (Bayer Korea, Seoul, Korea), chloramphenicol (Chong Kun Dang, Seoul, Korea), and tetracycline (Sigma Aldrich). For the piperacillin and tazobactam combination, a constant concentration of tazobactam (4 µg/mL) was added. An inoculum of 10⁵ colony forming units (CFUs) was applied with a Steers replicator (Craft Machine Inc., Woodline, PA, USA), and the plates were incubated in an anaerobic chamber (Forma Scientific, Marietta, OH, USA) for 48 hours at 37°C. Quality control was tested with the following two organisms: *B. fragilis* ATCC 25285 and *B. thetaiotaomicron* ATCC 29741. Double-disk potentiation tests (DPTs) with dipicolinic acid were carried out on Brucella agar to screen for carbapenemase-producing *B. fragilis* group isolates [20].

RESULTS

Anaerobic gram-negative isolates

Most of the gram-negative isolates tested were susceptible to piperacillin-tazobactam, imipenem, and meropenem, as their resistance rates to these three antimicrobials were <7% (Table 1). Low frequencies of resistance to chloramphenicol and metronidazole were observed for most of the anaerobic gram-negative bacterial isolates tested.

High rates of resistance to penicillin (98–100%), cefotetan (12–71%), and clindamycin (38–69%) were noted for the *B. fragilis* group isolates. The resistance of *B. fragilis* isolates to cefotetan was 12%; however, the non-*fragilis* *Bacteroides* Group II isolates showed high resistance to cefotetan (71%). Furthermore, *Parabacteroides* spp. (including *P. distasonis*), reclassified from the genus *Bacteroides*, showed very high resistance to cefotetan (95–100%). The resistance of *B. fragilis* and non-*fra-*

Table 1. Antimicrobial susceptibility of 521 anaerobic bacterial isolates from 2014 to 2016

N of isolates and antimicrobial agents	Breakpoint ($\mu\text{g/mL}$)			MIC ($\mu\text{g/mL}$)			Susceptibility (%)*		
	S	I	R	Range	50%	90%	S	I	R
<i>Bacteroides fragilis</i> (60)									
Penicillin	≤ 0.5	1	≥ 2	4->128	16	>128	0	0	100
Piperacillin-tazobactam	≤ 32	64	≥ 128	0.12->128	1	4	95	0	5
Cefoxitin	≤ 16	32	≥ 64	4-64	8	32	82	12	7
Cefotetan	≤ 16	32	≥ 64	2->128	8	64	75	13	12
Imipenem	≤ 4	8	≥ 16	$\leq 0.06-32$	0.12	1	95	0	5
Meropenem	≤ 4	8	≥ 16	$\leq 0.06->128$	0.12	2	92	3	5
Clindamycin	≤ 2	4	≥ 8	$\leq 0.06->128$	1	>128	60	2	38
Moxifloxacin	≤ 2	4	≥ 8	$\leq 0.06-32$	0.5	8	77	3	20
Chloramphenicol	≤ 8	16	≥ 32	4-8	4	8	100	0	0
Metronidazole	≤ 8	16	≥ 32	0.25-8	4	4	100	0	0
Non- <i>fragilis</i> <i>Bacteroides</i> group I (54) [†]									
Penicillin	≤ 0.5	1	≥ 2	$\leq 0.06->128$	128	>128	2	0	98
Piperacillin-tazobactam	≤ 32	64	≥ 128	$\leq 0.06->128$	8	32	93	2	6
Cefoxitin	≤ 16	32	≥ 64	1->128	16	32	57	35	7
Cefotetan	≤ 16	32	≥ 64	0.5->128	64	>128	17	24	59
Imipenem	≤ 4	8	≥ 16	$\leq 0.06-32$	0.5	2	94	4	2
Meropenem	≤ 4	8	≥ 16	$\leq 0.06-4$	0.5	2	100	0	0
Clindamycin	≤ 2	4	≥ 8	$\leq 0.06->128$	>128	>128	20	11	69
Moxifloxacin	≤ 2	4	≥ 8	$\leq 0.06-32$	2	8	78	7	15
Chloramphenicol	≤ 8	16	≥ 32	2-8	8	8	100	0	0
Metronidazole	≤ 8	16	≥ 32	0.5-8	2	4	100	0	0
Non- <i>fragilis</i> <i>Bacteroides</i> group II (14) [‡]									
Penicillin	≤ 0.5	1	≥ 2	16->128	16	>128	0	0	100
Piperacillin-tazobactam	≤ 32	64	≥ 128	0.5-32	8	32	100	0	0
Cefoxitin	≤ 16	32	≥ 64	1-64	32	32	43	50	7
Cefotetan	≤ 16	32	≥ 64	4->128	64	128	21	7	71
Imipenem	≤ 4	8	≥ 16	0.12-2	0.25	2	100	0	0
Meropenem	≤ 4	8	≥ 16	0.12-32	0.25	16	86	0	14
Clindamycin	≤ 2	4	≥ 8	0.5->128	>128	>128	36	0	64
Moxifloxacin	≤ 2	4	≥ 8	0.5-64	1	16	79	0	21
Chloramphenicol	≤ 8	16	≥ 32	4-8	8	8	100	0	0
Metronidazole	≤ 8	16	≥ 32	2-4	2	4	100	0	0
<i>Parabacteroides distasonis</i> (19)									
Penicillin	≤ 0.5	1	≥ 2	$\leq 0.06->128$	>128	>128	5	0	95
Piperacillin-tazobactam	≤ 32	64	≥ 128	$\leq 0.06->128$	32	>128	89	0	11
Cefoxitin	≤ 16	32	≥ 64	1-128	32	64	21	42	37
Cefotetan	≤ 16	32	≥ 64	1->128	128	>128	5	0	95
Imipenem	≤ 4	8	≥ 16	$\leq 0.06-64$	1	16	89	0	11
Clindamycin	≤ 2	4	≥ 8	$\leq 0.06->128$	>128	>128	5	16	79

(Continued to the next page)

Table 1. Continued

N of isolates and antimicrobial agents	Breakpoint (µg/mL)			MIC (µg/mL)			Susceptibility (%)*		
	S	I	R	Range	50%	90%	S	I	R
Moxifloxacin	≤2	4	≥8	0.12–32	0.5	16	79	0	21
Chloramphenicol	≤8	16	≥32	2–8	8	8	100	0	0
Metronidazole	≤8	16	≥32	0.5–4	2	4	100	0	0
<i>Parabacteroides</i> spp. (10) [§]									
Penicillin	≤0.5	1	≥2	8–>128	>128	>128	0	0	100
Piperacillin-tazobactam	≤32	64	≥128	2–32	16	32	100	0	0
Cefoxitin	≤16	32	≥64	16–64	32	64	20	50	30
Cefotetan	≤16	32	≥64	64–>128	128	>128	0	0	100
Imipenem	≤4	8	≥16	1–4	1	4	100	0	0
Clindamycin	≤2	4	≥8	0.5–>128	>128	>128	20	0	80
Moxifloxacin	≤2	4	≥8	0.25–16	0.5	16	60	10	30
Chloramphenicol	≤8	16	≥32	4–8	8	8	100	0	0
Metronidazole	≤8	16	≥32	1–4	2	4	100	0	0
<i>Prevotella</i> spp. (33) ^l									
Penicillin	≤0.5	1	≥2	≤0.06–>128	16	32	6	3	91
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–8	≤0.06	≤0.06	100	0	0
Cefoxitin	≤16	32	≥64	0.5–32	1	4	97	3	0
Cefotetan	≤16	32	≥64	0.5–64	2	32	88	9	3
Imipenem	≤4	8	≥16	≤0.06–1	≤0.06	≤0.06	100	0	0
Clindamycin	≤2	4	≥8	≤0.06–>128	≤0.06	>128	55	0	45
Moxifloxacin	≤2	4	≥8	0.12–64	0.5	4	70	21	9
Chloramphenicol	≤8	16	≥32	1–16	2	8	91	9	0
Metronidazole	≤8	16	≥32	0.12–32	1	8	91	6	3
<i>Fusobacterium</i> spp.(19) [¶]									
Penicillin	≤0.5	1	≥2	≤0.06–>128	0.25	4	79	5	16
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–8	2	4	100	0	0
Cefoxitin	≤16	32	≥64	0.12–16	4	8	100	0	0
Cefotetan	≤16	32	≥64	≤0.06–32	2	4	95	5	0
Imipenem	≤4	8	≥16	≤0.06–4	1	2	100	0	0
Meropenem	≤4	8	≥16	≤0.06–2	≤0.06	1	100	0	0
Clindamycin	≤2	4	≥8	≤0.06–128	2	16	58	21	21
Moxifloxacin	≤2	4	≥8	≤0.06–128	4	8	42	47	11
Chloramphenicol	≤8	16	≥32	≤0.06–2	2	2	100	0	0
Metronidazole	≤8	16	≥32	0.12–1	≤0.06	1	100	0	0
Other gram-negative bacilli (10)**									
Penicillin	≤0.5	1	≥2	≤0.06–>128	1	16	30	30	40
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–>128	1	128	80	0	20
Cefoxitin	≤16	32	≥64	0.25–32	2	32	80	20	0
Cefotetan	≤16	32	≥64	0.5–32	2	4	90	10	0
Imipenem	≤4	8	≥16	≤0.06–0.5	0.25	0.25	100	0	0

(Continued to the next page)

Table 1. Continued

N of isolates and antimicrobial agents	Breakpoint (µg/mL)			MIC (µg/mL)			Susceptibility (%) [*]		
	S	I	R	Range	50%	90%	S	I	R
Clindamycin	≤2	4	≥8	≤0.06–32	≤0.06	4	90	0	10
Moxifloxacin	≤2	4	≥8	≤0.06–16	0.5	16	50	10	40
Chloramphenicol	≤8	16	≥32	0.25–8	4	8	100	0	0
Metronidazole	≤8	16	≥32	≤0.06–64	NA	NA	NA	NA	NA
<i>Veillonella</i> spp. (11) ^{††}									
Penicillin	≤0.5	1	≥2	2–16	4	16	0	0	100
Piperacillin-tazobactam	≤32	64	≥128	4–128	16	32	91	0	9
Cefoxitin	≤16	32	≥64	2–8	4	8	100	0	0
Cefotetan	≤16	32	≥64	0.5–32	1	2	91	9	0
Imipenem	≤4	8	≥16	0.25–8	0.50	2	91	9	0
Clindamycin	≤2	4	≥8	≤0.06–>128	≤0.06	2	91	0	9
Moxifloxacin	≤2	4	≥8	≤0.06–64	0.25	4	82	9	9
Chloramphenicol	≤8	16	≥32	0.5–2	2	2	100	0	0
Metronidazole	≤8	16	≥32	2–32	8	32	73	0	27
<i>Finegoldia magna</i> (31)									
Penicillin	≤0.5	1	≥2	≤0.06–0.12	≤0.06	≤0.06	100	0	0
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–0.12	≤0.06	≤0.06	100	0	0
Cefoxitin	≤16	32	≥64	0.25–4	0.5	2	100	0	0
Cefotetan	≤16	32	≥64	0.12–4	0.25	2	100	0	0
Imipenem	≤4	8	≥16	≤0.06–≤0.06	≤0.06	≤0.06	100	0	0
Clindamycin	≤2	4	≥8	≤0.06–64	≤0.06	0.5	94	3	3
Moxifloxacin	≤2	4	≥8	0.12–8	0.25	0.5	94	0	6
Metronidazole	≤8	16	≥32	0.12–8	1	1	100	0	0
Tetracycline	≤4	8	≥16	≤0.06–16	0.25	4	94	0	6
<i>Parvimonas micra</i> (29)									
Penicillin	≤0.5	1	≥2	≤0.06–0.25	0.12	0.25	100	0	0
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–2	0.12	0.25	100	0	0
Cefoxitin	≤16	32	≥64	0.25–4	0.5	1	100	0	0
Cefotetan	≤16	32	≥64	0.5–2	1	2	100	0	0
Imipenem	≤4	8	≥16	≤0.06–0.25	≤0.06	0.12	100	0	0
Clindamycin	≤2	4	≥8	≤0.06–128	1	128	76	0	24
Moxifloxacin	≤2	4	≥8	≤0.06–32	2	32	52	0	48
Metronidazole	≤8	16	≥32	0.5–4	1	2	100	0	0
Tetracycline	≤4	8	≥16	1–64	16	32	45	0	55
Other gram-positive cocci (14) [†]									
Penicillin	≤0.5	1	≥2	≤0.06–8	0.12	8	64	0	36
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–16	0.25	16	100	0	0
Cefoxitin	≤16	32	≥64	≤0.06–16	0.50	16	100	0	0
Cefotetan	≤16	32	≥64	0.25–128	4	128	50	7	43
Imipenem	≤4	8	≥16	≤0.06–4	0.25	4	100	0	0

(Continued to the next page)

Table 1. Continued

N of isolates and antimicrobial agents	Breakpoint (µg/mL)			MIC (µg/mL)			Susceptibility (%)*		
	S	I	R	Range	50%	90%	S	I	R
Clindamycin	≤2	4	≥8	≤0.06–128	0.25	128	50	7	43
Moxifloxacin	≤2	4	≥8	0.12–16	2	8	64	7	29
Metronidazole	≤8	16	≥32	0.5–8	2	2	100	0	0
Tetracycline	≤4	8	≥16	0.25–64	32	64	14	0	86
<i>Clostridioides difficile</i> (15)									
Penicillin	≤0.5	1	≥2	2–4	2	4	0	0	100
Piperacillin-tazobactam	≤32	64	≥128	4–16	16	16	100	0	0
Cefoxitin	≤16	32	≥64	128–>128	128	>128	0	0	100
Cefotetan	≤16	32	≥64	16–64	32	64	20	40	40
Imipenem	≤4	8	≥16	4–64	16	32	7	0	93
Clindamycin	≤2	4	≥8	1–>128	16	>128	7	27	67
Moxifloxacin	≤2	4	≥8	1–32	16	32	47	0	53
Metronidazole	≤8	16	≥32	0.5–4	2	2	100	0	0
Tetracycline	≤4	8	≥16	0.25–32	0.5	32	60	13	27
<i>Clostridium</i> spp. (27) ⁱ									
Penicillin	≤0.5	1	≥2	≤0.06–2	0.5	2	74	15	11
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–32	0.5	16	100	0	0
Cefoxitin	≤16	32	≥64	0.25–128	2	64	85	4	11
Cefotetan	≤16	32	≥64	0.25–>128	4	>128	78	4	19
Imipenem	≤4	8	≥16	0.25–8	1	4	96	4	0
Clindamycin	≤2	4	≥8	≤0.06–>128	1	>128	63	4	33
Moxifloxacin	≤2	4	≥8	0.12–128	1	32	74	7	19
Metronidazole	≤8	16	≥32	0.25–64	2	8	93	0	7
Tetracycline	≤4	8	≥16	0.12–64	16	64	26	11	63
<i>Actinomyces odontolyticus</i> (34)									
Penicillin	≤0.5	1	≥2	≤0.06–8	0.5	8	53	18	29
Piperacillin-tazobactam	≤32	64	≥128	0.5–64	4	32	91	9	0
Cefoxitin	≤16	32	≥64	≤0.06–32	1	16	97	3	0
Cefotetan	≤16	32	≥64	0.5–128	8	128	65	12	24
Imipenem	≤4	8	≥16	≤0.06–8	0.5	2	97	3	0
Clindamycin	≤2	4	≥8	≤0.06–>128	0.5	>128	62	0	38
Moxifloxacin	≤2	4	≥8	2–32	2	2	97	0	3
Metronidazole	≤8	16	≥32	8–>128	32	>128	6	29	65
Tetracycline	≤4	8	≥16	2–32	2	16	79	0	21
<i>Actinomyces</i> spp. (23) ⁱⁱ									
Penicillin	≤0.5	1	≥2	≤0.06–0.5	0.12	0.12	100	0	0
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–1	0.5	1	100	0	0
Cefoxitin	≤16	32	≥64	0.12–1	0.25	1	100	0	0
Cefotetan	≤16	32	≥64	≤0.06–4	0.5	4	100	0	0
Imipenem	≤4	8	≥16	≤0.06–0.25	≤0.06	0.25	100	0	0

(Continued to the next page)

Table 1. Continued

N of isolates and antimicrobial agents	Breakpoint (µg/mL)			MIC (µg/mL)			Susceptibility (%)*		
	S	I	R	Range	50%	90%	S	I	R
Clindamycin	≤2	4	≥8	≤0.06–>128	0.25	>128	78	0	22
Moxifloxacin	≤2	4	≥8	0.5–2	1	2	100	0	0
Metronidazole	≤8	16	≥32	32–>128	>128	>128	0	0	100
Tetracycline	≤4	8	≥16	0.5–64	1	32	78	0	22
<i>Bifidobacterium</i> spp. (18)**									
Penicillin	≤0.5	1	≥2	≤0.06–4	0.12	4	72	11	17
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–32	0.12	16	100	0	0
Cefoxitin	≤16	32	≥64	≤0.06–64	1	64	83	0	17
Cefotetan	≤16	32	≥64	0.25–>128	2	>128	72	0	28
Imipenem	≤4	8	≥16	≤0.06–1	0.12	0.5	100	0	0
Clindamycin	≤2	4	≥8	≤0.06–>128	0.5	>128	72	0	28
Moxifloxacin	≤2	4	≥8	≤0.06–16	1	4	89	6	6
Metronidazole	≤8	16	≥32	0.5–>128	8	>128	67	11	22
Tetracycline	≤4	8	≥16	2–128	2	16	83	6	11
<i>Eggerthella lenta</i> (38)									
Penicillin	≤0.5	1	≥2	0.5–2	1	2	8	45	47
Piperacillin-tazobactam	≤32	64	≥128	16–32	16	32	100	0	0
Cefoxitin	≤16	32	≥64	2–32	8	16	95	5	0
Cefotetan	≤16	32	≥64	32–>128	128	>128	0	5	95
Imipenem	≤4	8	≥16	0.5–0.5	0.5	1	100	0	0
Clindamycin	≤2	4	≥8	0.12–0.5	0.5	>128	63	0	37
Moxifloxacin	≤2	4	≥8	0.12–4	4	64	47	21	32
Metronidazole	≤8	16	≥32	0.5–1	1	1	100	0	0
Tetracycline	≤4	8	≥16	0.5–32	32	64	37	3	61
<i>Lactobacillus</i> spp. (36)***									
Penicillin	≤0.5	1	≥2	≤0.06–>128	0.5	2	56	22	22
Piperacillin-tazobactam	≤32	64	≥128	0.5–>128	4	8	94	0	6
Cefoxitin	≤16	32	≥64	4–>128	>128	>128	17	3	81
Cefotetan	≤16	32	≥64	8–>128	>128	>128	3	0	97
Imipenem	≤4	8	≥16	≤0.06–16	0.25	8	86	11	3
Clindamycin	≤2	4	≥8	≤0.06–1	0.12	0.5	100	0	0
Moxifloxacin	≤2	4	≥8	0.25–4	1	2	94	6	0
Metronidazole	≤8	16	≥32	32–>128	>128	>128	0	0	100
Tetracycline	≤4	8	≥16	0.5–>128	8	32	44	33	22
Other gram-positive bacilli (26)†††									
Penicillin	≤0.5	1	≥2	≤0.06–4	0.12	0.25	96	0	4
Piperacillin-tazobactam	≤32	64	≥128	≤0.06–2	0.12	2	100	0	0
Cefoxitin	≤16	32	≥64	≤0.06–16	1	4	100	0	0
Cefotetan	≤16	32	≥64	≤0.06–32	2	8	96	4	0
Imipenem	≤4	8	≥16	≤0.06–0.5	≤0.06	0.12	100	0	0

(Continued to the next page)

lates (including *Parabacteroides* spp.) are the most clinically significant anaerobes because they are commonly isolated from clinical specimens and show greater virulence and resistance than most other anaerobes [10]. The resistance of *B. fragilis* isolates to cefotetan remained low for several years: 14% in 1997–2004 [8], 14% in 2007–2008 [7], 13% in 2009–2012 [9], and 12% in 2014–2016.

The resistance of *B. fragilis* isolates to moxifloxacin has steadily increased over the past 11 years, from 11% in 2007–2008 to 20% in 2014–2016. The current values are similar to those observed in 2010–2012 in the USA (19.1%) [21]. The resistance to moxifloxacin among non-*fragilis* *Bacteroides* group species has not increased; the rates have ranged from 18% in 2007–2008 to 16% in 2014–2016 [7]. This may reflect the fact that the *B. fragilis* group includes former members of the group previously reclassified as *Parabacteroides* spp. [7]. *Parabacteroides* spp. had a higher resistance rate to clindamycin and a lower resistance rate to moxifloxacin compared with isolates in the USA (50% and 44%, respectively) [21].

We observed that non-*fragilis* *Bacteroides* Group II had higher resistance rates to meropenem than imipenem, while non-*fragilis* *Bacteroides* Group I demonstrated the opposite pattern. Such patterns have been previously reported by S6ki *et al.* [22]; however, they did not include the carbapenem resistance patterns of non-*fragilis* *Bacteroides* Group II.

Prevotella spp. were highly susceptible to most antimicrobials except penicillin and clindamycin. The resistance rates to clindamycin remained high, at 45%, for *Prevotella* spp., compared with 50% in 2007–2008 [7]. Only one *Prevotella* spp. isolate was resistant to metronidazole. This represents an even lower rate of resistance than that reported in Greece (8%) [23]. The *Veillonella* resistance rate to metronidazole was 27%, higher than that reported in the USA (11%) [4].

The anaerobic GPC isolates exhibited various rates of resistance to penicillin, clindamycin, and metronidazole [2]. However, the resistance rate of GPC to clindamycin, moxifloxacin, and tetracycline varied across species. The resistance of *C. difficile* to imipenem has rapidly increased over the past years, from 8% in 2007–2008 to 93% in 2014–2016 [7]. There is a general assumption that resistance varies with ribotype; Lee *et al.* [24] showed that ribotypes O17 and O18 have high MICs for moxifloxacin and imipenem, compared with ribotype O01. Metronidazole-resistant isolates were common among *Actinomyces* and *Lactobacillus* spp. A study in Argentina showed that all *Actinomyces* spp. were susceptible to penicillin, and 21.2% were resistant to clindamycin [25]. *E. lenta* has been commonly as-

sociated with gastrointestinal infections; its overall mortality is significant, ranging from 36% to 48% [26, 27]. The *E. lenta* resistance rates we observed were much higher than those in Australia (0% for penicillin and 12% for moxifloxacin) [26].

The limitations of this study were the small number of re-named and reclassified bacteria and bacterial isolates collected. Further, it was a single-center, retrospective study.

In conclusion, piperacillin-tazobactam, ceftioxin, and carbapenems were β -lactam agents highly active against most of the anaerobic bacteria we tested. However, recently renamed non-*fragilis* *Bacteroides* group isolates showed resistance to meropenem (14%). These data suggest the importance of ongoing surveillance to provide clinically relevant information to clinicians for the empirical management of infections caused by anaerobic organisms. Continuous monitoring is necessary to detect changes in antimicrobial resistance patterns.

Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgements

We wish to thank Seungeun Ji and Young Hee Seo for their technical assistance. This study was supported by a faculty research grant from Yonsei University (6-2016-0071).

REFERENCES

1. Schuetz AN. Antimicrobial resistance and susceptibility testing of anaerobic bacteria. *Clin Infect Dis* 2014;59:698-705.
2. Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. *Anaerobe* 2006;12:115-21.
3. Lee Y, Park YJ, Kim MN, Uh Y, Kim MS, Lee K. Multicenter study of antimicrobial susceptibility of anaerobic bacteria in Korea in 2012. *Ann Lab Med* 2015;35:479-86.
4. Hastey CJ, Boyd H, Schuetz AN, Anderson K, Citron DM, Dzink-Fox J, et al. Changes in the antibiotic susceptibility of anaerobic bacteria from 2007–2009 to 2010–2012 based on the CLSI methodology. *Anaerobe* 2016;42:27-30.
5. CLSI. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. 8th ed. CLSI M11-A8. Wayne, PA: Clinical and Laboratory Standards Institute. 2012.
6. Lee K, Shin HB, Chong Y. Antimicrobial resistance patterns of *Bacteroides fragilis* group organisms in Korea. *Yonsei Med J* 1998;39:578-86.
7. Lee Y, Park Y, Kim MS, Yong D, Jeong SH, Lee K, et al. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. *Antimicrob Agents Chemother* 2010;54:3993-7.
8. Roh KH, Kim S, Kim CK, Yum JH, Kim MS, Yong D, et al. Resistance

- trends of *Bacteroides fragilis* group over an 8-year period, 1997-2004, in Korea. Korean J Lab Med 2009;29:293-8.
9. Yim J, Lee Y, Kim M, Seo YH, Kim WH, Yong D, et al. Antimicrobial susceptibility of clinical isolates of *Bacteroides fragilis* group organisms recovered from 2009 to 2012 in a Korean hospital. Ann Lab Med 2015; 35:94-8.
 10. Wexler HM. *Bacteroides*: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007;20:593-621.
 11. Sóki J, Hedberg M, Patrick S, Bálint B, Herczeg R, Nagy I, et al. Emergence and evolution of an international cluster of MDR *Bacteroides fragilis* isolates. J Antimicrob Chemother 2016;71:2441-8.
 12. Merchan C, Parajuli S, Siegfried J, Scipione MR, Dubrovskaya Y, Rahimian J. Multidrug-resistant *Bacteroides fragilis* bacteremia in a US resident: an emerging challenge. Case Rep Infect Dis 2016;2016:3607125.
 13. Sakamoto M and Benno Y. Reclassification of *Bacteroides distasonis*, *Bacteroides goldsteinii* and *Bacteroides merdae* as *Parabacteroides distasonis* gen. nov., comb. nov., *Parabacteroides goldsteinii* comb. nov. and *Parabacteroides merdae* comb. nov. Int J Syst Evol Microbiol 2006; 56:1599-605.
 14. Huys G, Vancanneyt M, D'Haene K, Falsen E, Wauters G, Vandamme P. *Alloscardovia omnicoles* gen. nov., sp. nov., from human clinical samples. Int J Syst Evol Microbiol 2007;57:1442-6.
 15. Downes J, Olsvik B, Hiom SJ, Spratt DA, Cheeseman SL, Olsen I, et al. *Bulleidia extracta* gen. nov., sp. nov., isolated from the oral cavity. Int J Syst Evol Microbiol 2000;50:979-83.
 16. Tee W, Midolo P, Janssen PH, Kerr T, Dyal-Smith ML. Bacteremia due to *Leptotrichia trevisanii* sp. nov. Eur J Clin Microbiol Infect Dis 2001;20: 765-9.
 17. Rautio M, Eerola E, Väisänen-Tunkelrott ML, Molitoris D, Lawson P, Collins MD, et al. Reclassification of *Bacteroides putredinis* (Weinberg et al., 1937) in a new genus *Alistipes* gen. nov., as *Alistipes putredinis* comb. nov., and description of *Alistipes finegoldii* sp. nov., from human sources. Syst Appl Microbiol 2003;26:182-8.
 18. Song Y, Könönen E, Rautio M, Liu C, Bryk A, Eerola E, et al. *Alistipes onderdonkii* sp. nov. and *Alistipes shahii* sp. nov., of human origin. Int J Syst Evol Microbiol 2006;56:1985-90.
 19. CLSI. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. 27th ed. CLSI M100. Wayne, PA: Clinical and Laboratory Standards Institute. 2017.
 20. Yong D, Lee Y, Jeong SH, Lee K, Chong Y. Evaluation of double-disk potentiation and disk potentiation tests using dipicolinic acid for detection of metallo- β -lactamase-producing *Pseudomonas* spp. and *Acinetobacter* spp. J Clin Microbiol 2012;50:3227-32.
 21. Snyderman DR, Jacobus NV, McDermott LA, Goldstein EJ, Harrell L, Jenkins SG, et al. Trends in antimicrobial resistance among *Bacteroides* species and *Parabacteroides* species in the United States from 2010-2012 with comparison to 2008-2009. Anaerobe 2017;43:21-6.
 22. Sóki J, Edwards R, Hedberg M, Fang H, Nagy E, Nord CE, et al. Examination of *cfiA*-mediated carbapenem resistance in *Bacteroides fragilis* strains from a European antibiotic susceptibility survey. Int J Antimicrob Agents 2006;28:497-502.
 23. Papaparaskevas J, Pantazatou A, Katsandri A, Houhoula DP, Legakis NJ, Tsakris A, et al. Moxifloxacin resistance is prevalent among *Bacteroides* and *Prevotella* species in Greece. J Antimicrob Chemother 2008; 62:137-41.
 24. Lee JH, Lee Y, Lee K, Riley TV, Kim H. The changes of PCR ribotype and antimicrobial resistance of *Clostridium difficile* in a tertiary care hospital over 10 years. J Med Microbiol 2014;63:819-23.
 25. Barberis C, Budia M, Palombarani S, Rodriguez CH, Ramirez MS, Arias B, et al. Antimicrobial susceptibility of clinical isolates of *Actinomyces* and related genera reveals an unusual clindamycin resistance among *Actinomyces urogenitalis* strains. J Glob Antimicrob Resist 2017;8:115-20.
 26. Lee MR, Huang YT, Liao CH, Chuang TY, Wang WJ, Lee SW, et al. Clinical and microbiological characteristics of bacteremia caused by *Eggerthella*, *Paraeggerthella* and *Eubacterium* species at a university hospital in Taiwan, 2001-2010. J Clin Microbiol 2012;50:2053-5.
 27. Venugopal AA, Szpunar S, Johnson LB. Risk and prognostic factors among patients with bacteremia due to *Eggerthella lenta*. Anaerobe 2012;18:475-8.